MIDWEST EAR, NOSE & THROAT SPECIALISTS AMONG FIRST IN NATION TO OFFER NEW FDA-APPROVED TREATMENT FOR OBSTRUCTIVE SLEEP APNEA
Inspire® therapy is a promising option for people not getting consistent benefit from CPAP
We are one of the first sites in the United States to offer Inspire therapy for people suffering from Obstructive Sleep Apnea (OSA). Inspire therapy utilizes first-of-its-kind technology—a small, fully implanted system that has been clinically proven to significantly reduce sleep apnea events and significantly improve quality of life measures.
OSA affects an estimated 18 million Americans and occurs when the tongue and other soft tissues relax during sleep and obstruct the airway. This causes recurrent awakening and leads to daytime sleepiness or fatigue and increased risk of heart attack, stroke, weight gain, and high blood pressure.
Inspire therapy senses breathing patterns and delivers mild stimulation to key airway muscles, which keeps the airway open during sleep. Inspire therapy is a promising new treatment option for people that are not receiving consistent benefits from continuous positive airway pressure (CPAP).
“We believe that this therapy represents a major advance in sleep apnea treatment, especially for vulnerable patients who cannot achieve benefit from CPAP,” said Dr. Kristin Gendron, Otolaryngologist, Midwest Ear, Nose & Throat Specialists. “Untreated moderate-to-severe OSA places patients at increased risk for cardiovascular disease, accidents, and death. Inspire therapy provides us with an effective new treatment to use in a select group of our CPAP intolerant patient population.”
Inspire therapy is a clinically proven solution. Results from the STAR trial, a clinical study conducted at 22 leading medical centers in the United States and Europe, were recently published in the New England Journal of Medicine. STAR trial results showed that Inspire therapy reduced apnea events by 68% and significantly improved key quality of life measures.
Inspire therapy is FDA approved for a subset of moderate to severe sleep apnea patients who are unable to use CPAP who also have:
- AHI range 20-65 events per hour
- Less than 25% central sleep apnea
- No complete concentric collapse at the palate
Indications, contraindications and safety information can be reviewed at www.InspireSleep.com.
Join Midwest Ear, Nose & Throat Specialists and Inspire Therapy for a Community Health Talk on Thursday, November 6th and Thursday November 20th from 6:00 PM – 7:00 PM at our Woodbury location. Please visit InspireSleep to register.